Abate AS consolidated revenue surges to ₹159.4 cr

Tipsheet Editorial — Thu, 11 Jun 2026 20:14:55 GMT

Subsidiary consolidation drives consolidated revenue from ₹14.1 cr to ₹159.4 cr; net profit jumps to ₹12.3 cr.

What’s new

Consolidated revenue surged to ₹159.4 cr from ₹14.1 cr in FY26.
Net profit rose to ₹12.3 cr from ₹1.1 cr.
Standalone business revenue stood at ₹2.1 cr; auditor's report formatting error corrected.

Why it matters

The company has transitioned from a negligible revenue base to a substantial enterprise, driven by inclusion of subsidiaries in trading and services. The unmodified audit opinion adds credibility to the reported figures, marking a credible scale-up.

What we’re watching

Whether revenue growth sustains as subsidiaries integrate further.
Standalone business remains tiny at ₹2.1 cr: any plans to scale?
Low debt/equity of 0.06 leaves room for further expansion.

The full read

Abate AS Industries has delivered a dramatic scale-up in FY26. Consolidated revenue hit ₹159.4 crore, up from ₹14.1 crore in the prior year, driven by the inclusion of subsidiaries in trading and services. Net profit rose to ₹12.3 crore from ₹1.1 crore. The standalone business remains negligible at ₹2.1 crore in revenue and ₹1.5 crore in profit. An unmodified audit opinion gives the numbers weight, and a minor formatting error in the auditor's report has been corrected. With a market cap of ₹164 crore and a trailing P/E of 19.2, the stock now trades at a modest multiple to the new earnings base. The open question is whether the revenue jump is sustainable and what the company does with its small standalone core.

Primary source: BSE · NSE

Abate AS posts first positive cash flow as profit jumps tenfold on 67% revenue surge

Tipsheet Editorial — Thu, 04 Jun 2026 19:03:51 GMT

The healthcare-focused firm hit ₹162 cr in revenue and ₹12.3 cr in profit in FY26, its best year yet, and is now planning a ₹50 cr expansion push.

What’s new

Abate AS revenue climbed 67% to nearly ₹162 cr in FY26; profit rose tenfold to ₹12.3 cr.
The company posted its first-ever positive operating cash flow of ₹6.1 cr.
Management outlined plans to push the healthcare revenue mix to 70-80% and flagged a ₹50 cr capex requirement.

Why it matters

The numbers are strong, but the real shift is strategic. Abate AS is deliberately pivoting toward healthcare services, targeting an 18-20% EBITDA margin and a dominant regional position. The ₹50 cr capital spend is the price of that transition, and the first positive cash flow gives it some internal funding to work with.

What we’re watching

How quickly the healthcare revenue mix actually reaches the 70-80% target.
Whether the ₹50 cr capex is funded via debt, internal accruals, or equity.
Margin stability as the company scales into higher-margin services.

The full read

Abate AS Industries just posted its best year. Revenue climbed 67% to nearly ₹162 cr, and profit jumped tenfold to ₹12.3 cr. The company also achieved its first positive operating cash flow of ₹6.1 cr, a key milestone that changes its funding profile. But the numbers are only half the story. Management laid out a clear plan to become a regional healthcare leader, targeting a healthcare revenue mix of 70-80% and an EBITDA margin of 18-20%. That transition will require ₹50 cr in capital expenditure, a significant commitment for a company this size. The first positive cash flow gives it a small internal war chest, but the open question is how it funds the rest. The pivot is on. Whether the margins follow is the next test.

Primary source: BSE · NSE

Abate AS Industries Ltd. (ABATEAS) — Tipsheet

Abate AS consolidated revenue surges to ₹159.4 cr

What’s new

Why it matters

What we’re watching

The full read

Abate AS posts first positive cash flow as profit jumps tenfold on 67% revenue surge

What’s new

Why it matters

What we’re watching

The full read